Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline plc : GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/09/2011 | 07:30am CET

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 08 December 2011, London, UK

- Improvement in disease-free survival does not reach statistical significance in study of delayed adjuvant therapy with lapatinib (Tykerb or Tyverb) monotherapy in HER2 positive breast cancer.

Results from TEACH (Tykerb Evaluation After Chemotherapy) were presented today at the 2011 CRTC-AACR San Antonio Breast Cancer Symposium.  TEACH is a randomised, double-blind, placebo-controlled Phase III trial to evaluate the effects of lapatinib monotherapy when given to women who were diagnosed with HER2 positive breast cancer, received treatment excluding trastuzumab, and remained disease free.  The median time from diagnosis to study entry was 3 years. Use of lapatinib in the delayed adjuvant setting is investigational only and not approved by regulatory authorities anywhere in the world.  

The primary objective of the study was to compare disease-free survival (DFS) between women receiving lapatinib and those receiving placebo.  More than 3000 women who completed neo-adjuvant or adjuvant chemotherapy, did not receive trastuzumab and did not have evidence of disease were randomised to receive lapatinib or placebo for up to 12 months or until a DFS event, defined as objective disease recurrence, a second primary cancer, contralateral breast cancer  or death from any cause.  After a median follow up of 4 years, DFS events occurred in 13% of patients in the lapatinib arm and 17% of patients in the placebo arm of the trial (Hazard Ratio = 0.83 95% Confidence Interval, 0.70 to 1.00; stratified log-rank 2-sided p=0.053).  Therefore, although an improvement in disease-free survival in favor of lapatinib was observed, this result did not meet the prespecified criteria for statistical significance.

Serious adverse events were reported in 6% of the lapatinib arm and 5% of the placebo arm.  The rate of Grade 3 diarrhoea was 6% in the lapatinib arm and <1% in the placebo arm (no Grade 4 events).  The rate of Grade 3 rash was 5% in the lapatinib arm and <1% in the placebo arm.  There was one Grade 4 rash event in the lapatinib arm   Hepatobiliary adverse events of Grade 3/4 severity were reported in 2% of the lapatinib arm and <1% of the placebo arm.    

"Although we are disappointed that the improvement in disease-free survival with lapatinib monotherapy in TEACH did not reach statistical significance, lapatinib combination therapy remains an important treatment option for patients with metastatic Her2+ breast cancer whose disease has progressed on treatment with trastuzumab-based regimens," said Rafael Amado, Senior Vice President Oncology Development.  "We look forward to the results from ongoing clinical trials with lapatinib in different combinations and lines of therapy, including the adjuvant setting, to assess the optimal use of lapatinib in women with HER2 positive breast cancer."  

Lapatinib was first approved for use in combination therapy in the metastatic setting in 2007 and is currently approved in 107 countries including the U.S., Europe, Australia, India, Brazil, Russia, Turkey, South Korea and other countries around the world.  

About TEACH:  The TEACH trial (Tykerb Evaluation After CHemotherapy; EGF105485) is a Phase III,  randomised, double-blind, placebo-controlled, study of lapatinib versus placebo in women with HER2-positive breast cancer who have not been previously treated with trastuzumab.  Most (55%) of the patients did not receive treatment with trastuzumab because they had completed treatment before trastuzumab was available and it was not institutional practice to use trastuzumab in the delayed adjuvant setting.  22% of the women enrolled in TEACH did not have access to trastuzumab because it was not available in their country or investigative centre and the remaining women were not treated with trastuzumab due to other reasons, including patient preference/convenience.  HER2 status for study entry was initially determined by immunohistochemistry (IHC) testing or fluorescent in situ hybridization (FISH) at local laboratories or at a central laboratory if HER2 status was unknown locally.  All patients' HER2 status was subsequently evaluated at a central laboratory using FISH.  The primary objective was to compare disease-free survival (DFS) between women treated with lapatinib and those treated with placebo in the early and delayed adjuvant treatment settings in a unique patient population.  TEACH was conducted in collaboration with Massachusetts General Hospital and more than 450 investigative centres in more than 30 countries participated in this study. 

About lapatinib (Tykerb or Tyverb)

In Europe, lapatinib, in combination with an aromatase inhibitor (AI), is indicated for the treatment of post-menopausal women with hormone receptor (HR)-positive, HER2 (ErbB2) over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended.  In Europe, lapatinib is also approved in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours over-express HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.  

In the United States, lapatinib is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that over-expresses the HER2 receptor for whom hormonal therapy is indicated.  Lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.  Lapatinib is also FDA approved in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours over-express HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.  

US FDA boxed warning and important safety information for Tykerb

Hepatotoxicity has been observed in clinical trials and post marketing experience.  The hepatotoxicity may be severe and deaths have been reported.  Causality of the deaths is uncertain.  Patients with known severe hypersensitivity to TYKERB or any of its components should not take TYKERB.  Also, patients may experience decreased left ventricular ejection fraction, hepatotoxicity, diarrhoea, interstitial lung disease/pneumonitis, QT prolongation, and risk of fetal harm in pregnant women.  If TYKERB is to be administered to patients with severe hepatic impairment, dose reduction should be considered.  The most common adverse reactions during therapy with TYKERB plus letrozole compared to letrozole were diarrhoea, rash, nausea, and fatigue.  The most common adverse reactions during therapy with TYKERB plus capecitabine versus capecitabine alone were diarrhoea, palmar-plantar erythrodysesthesia, nausea, rash, vomiting, and fatigue.  

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

Stephen Rea

+44 (0) 20 8047 5502

(London)

Sarah Spencer

+44 (0) 20 8047 5502

(London)

David Daley

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Kevin Colgan

+1 919 483 2839

(North Carolina)

Mary Anne Rhyne

+1 919 483 2839

(North Carolina)

Sarah Alspach

+1 919 483 2839

(Washington, DC)

Jennifer Armstrong

+1 919 483 2839

(Philadelphia)

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

Tom Curry

+ 1 215 751 5419

(Philadelphia)

Gary Davies

+ 44 (0) 20 8047 5503

(London)

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.



share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 GLAXOSMITHKLINE : *jefferies raises glaxosmithkline price target to 1800 pence -..
02/16 ASTRAZENECA : Milan mayor sees EU picking new home for drugs agency by June
02/16DJVECTURA : Hits GBP9 Million Royalty Target on Glaxo's Ellipta Products
02/16 Vectura Hits GBP9 Million Royalty Cap Under Skyepharma Legacy Deal
02/14 Gilead challenges GSK with strong HIV drug data
02/14 GLAXOSMITHKLINE : ViiV Gets Encouraging HIV Treatment Trial Results
02/14 GLAXOSMITHKLINE : ViiV Healthcare announces detailed positive phase III results ..
02/13 GLAXOSMITHKLINE : *jpmorgan raises glaxosmithkline price target to 1670 pence - ..
02/10 GILEAD SCIENCES, INC. (NASDAQ : GILD), GlaxoSmithKline Plc (NYSE:GSK) Battle Hea..
More news
Sector news : Pharmaceuticals - NEC
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 ASTRAZENECA : Top AstraZeneca shareholder Woodford adds to stake, bullish on out..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
02/17DJASTRAZENECA : Trial For Breast Cancer Treatment Shows Positive Results
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/17 What Makes Amgen A Compelling Buy In 2017?
02/17 Take The Road Less Traveled
02/16 Can Axovant Sciences Deliver In 2017?
02/15 Gilead And Glaxo's HIV Battle Intensifies
02/14 Gilead Will Free-Fall In Spite Of Carl Icahn
Advertisement
Financials ( GBP)
Sales 2017 29 875 M
EBIT 2017 8 344 M
Net income 2017 4 187 M
Debt 2017 13 565 M
Yield 2017 4,88%
P/E ratio 2017 20,14
P/E ratio 2018 17,03
EV / Sales 2017 3,15x
EV / Sales 2018 3,01x
Capitalization 80 506 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 17,7  GBP
Spread / Average Target 7,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC4.96%99 883
JOHNSON & JOHNSON3.17%323 362
ROCHE HOLDING LTD.4.69%210 814
PFIZER INC.3.51%204 018
NOVARTIS AG3.91%202 998
MERCK & CO., INC.11.08%180 289
More Results